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Abstract
Background: Chronic fibrosing idiopathic interstitial pneumonia (IIP) is characterized by alveolar epithelial damage,
activation of fibroblast proliferation, and loss of normal pulmonary architecture and function. This study aims to
investigate the genetic backgrounds of IIP through gene expression profiling and pathway analysis, and to identify
potential biomarkers that can aid in diagnosis and serve as novel therapeutic targets.
Methods: RNA extracted from lung specimens of 12 patients with chronic fibrosing IIP was profiled using Illumina
Human WG-6 v3 BeadChips, and Ingenuity Pathway Analysis was performed to identify altered functional and
canonical signaling pathways. For validating the results from gene expression analysis, immunohistochemical
staining of 10 patients with chronic fibrosing IIP was performed.
Results: Ninety-eight genes were upregulated in IIP patients relative to control subjects. Some of the upregulated
genes, namely desmoglein 3 (DSG3), protocadherin gamma-A9 (PCDHGA9) and discoidin domain-containing
receptor 1 (DDR1) are implicated in cell-cell interaction and/or adhesion; some, namely collagen type VII, alpha 1
(COL7A1), contactin-associated protein-like 3B (CNTNAP3B) and mucin-1 (MUC1) are encoding the extracellular matrix
molecule or the molecules involved in cell-matrix interactions; and the others, namely CDC25C and growth factor
independent protein 1B (GFI1B) are known to affect cell proliferation by affecting the progression of cell cycle or
regulating transcription. According to pathway analysis, alternated pathways in IIP were related to cell death and
survival and cellular growth and proliferation, which are more similar to cancer than to inflammatory response and
immunological diseases. Using immunohistochemistry, we further validate that DSG3, the most highly upregulated
gene, shows higher expression in chronic fibrosing IIP lung as compared to control lung.
Conclusion: We identified several genes upregulated in chronic fibrosing IIP patients as compared to control, and
found genes and pathways implicated in cancer, rather than in inflammatory or immunological disease to play
important roles in the pathogenesis of IIPs. Moreover, DSG3 is a novel potential biomarker for chronic fibrosing IIP
with its significantly high expression in IIP lung.
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Background
Idiopathic interstitial pneumonia (IIP) encompasses a
group of diffuse parenchymal lung diseases character-
ized by interstitial involvement resulting from various
patterns of inflammation and fibrosis of unknown
cause. Based on histological features, IIP has been fur-
ther classified into several subtypes, including idio-
pathic pulmonary fibrosis (IPF), which has the hallmark
histopathologic feature described as usual interstitial
pneumonia and nonspecific interstitial pneumonia
(NSIP) [1–3]. The latest statement from American
Thoracic Society (ATS) and European Respiratory Soci-
ety (ERS) proposed the category “chronic fibrosing IIP”
encompassing both IPF and NSIP [3], because separ-
ation between these two diseases is difficult, with sig-
nificant clinical, radiological, and pathological overlap
between them [4].
IPF is one of the most common and aggressive
types of IIP and is characterized by alveolar epithelial
damage that leads to inadequate tissue repair, collagen
accumulation, and fibroblast proliferation, although
the underlying molecular mechanisms remain unclear
[5]. Over the last decade, the few therapeutic options
available have not been very effective and the out-
come of IPF patients is poor [6]. Pirfenidone is the
first anti-fibrotic agent to be approved for IPF treat-
ment, with its efficacy and tolerability supported by
several clinical trials and surveillance [7–10]. Re-
cently, nintedanib, a multiple tyrosine kinase inhibitor,
also demonstrated clinical efficacy for IPF patients
[11]. However, these drugs only reduce the decline in
forced vital capacity, without halting disease progres-
sion in all patients. Therefore, new diagnostic tools
and therapeutic strategies, including molecular target-
ing drugs, are urgently needed.
Systematic analysis of the expression level of thou-
sands of genes using microarray is an effective approach
for identifying molecules that are altered in pulmonary
fibrosis or after treatment with anti-fibrotic agents [12].
Our group, as well as others, have performed high-
throughput screens combined with gene expression ana-
lysis of lung diseases including cancers, and identified
various potential targets for the development of new
diagnostic tools and therapies [13–16]. However, few
such analyses have been performed for IIP [17–21], and
most of these studies have been performed in Caucasian
populations with very limited data available from Japa-
nese populations.
The present study aims to delineate the molecular
mechanisms of pulmonary fibrosis and identify potential
disease-specific biomarkers and/or therapeutic targets in
the chronic fibrosing IIPs patients by using genome-
wide microarray analysis followed by canonical pathway
analysis.
Methods
Patients and clinical samples
Tissue samples were obtained by surgical lung biopsy
from Japanese patients with newly diagnosed IIP at the
Hiroshima University Hospital (Hiroshima, Japan) and
who have never taken medication for IIPs before. All
surgical lung specimens were immediately frozen and
stored at −80 °C for later analysis. Each patient under-
went physical examination, pulmonary function tests,
high-resolution computed tomography, bronchoscopy,
and bronchoalveolar lavage. IPF and NSIP were diag-
nosed according to the ATS/ERS criteria published in
2002 [22]. Patients with evidence of collagen vascular
disease, chronic hypersensitivity pneumonia, and other
known causes of interstitial lung diseases (ILDs) were
excluded. Control lung specimens for microarray ana-
lysis consisted of total RNA from three lungs (Cauca-
sians aged 32–61 years; cause of death: sudden death)
purchased from BD Biosciences Clontech (Lot Number
7080277; Palo Alto, CA, USA). Control tissues for im-
munohistochemistry were obtained from the healthy
areas of lungs, removed locally, along with lung tumors.
This study was approved by the Ethics Committee of
Hiroshima University Hospital (IRB M33 and 326) and
conducted in accordance with ethical standards estab-
lished in the Helsinki Declaration of 1975. All partici-
pants provided written informed consent for the use of
tissue specimens for the study and the publication of
their individual data. Clinical characteristics of the 12
IIP patients are summarized in Table 1.
RNA isolation and gene expression profiling
Gene expression profiles of frozen tissue specimens from
12 IIP patients, derived from the central part of the surgi-
cal lung biopsy, were analyzed by GP Biosciences Ltd.
Table 1 Clinical characteristics of idiopathic interstitial
pneumonia cases
Variables Microarray cohort IHC cohort
(n = 12) (n = 10)
Age (years) 66.2 ± 2.1 63.1 ± 1.9
Gender (male/female)* 9/3 7/3
Smoking history
(Smoker/non-smoker) *
9/3 7/3
Pack-years* 23.8 ± 6.9 26.4 ± 7.8
Disease category (IPF/ NSIP) 7/5 5/5
Pulmonary function test
VC (% predicted) 86.0 ± 6.2 88.9 ± 6.6
DLco (% predicted) 57.2 ± 5.3 54.1 ± 5.5
Values are expressed as mean ± SEM or as a number
*P < 0.05 (Mann-Whitney U or χ2 test between two groups)
IHC immunohistochemical analysis, IPF idiopathic pulmonary fibrosis, NSIP
nonspecific interstitial pneumonia, VC vital capacity, DLCO single-breath carbon
monoxide diffusing capacity
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(Kanagawa, Japan). RNA quality was verified using the
RNA6000 Nano Assay on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Illumina
Human WG-6 v3 BeadArrays (Illumina Inc., San Diego,
CA, USA) with about 48,000 transcripts were used ac-
cording to the manufacturer’s instructions. An Illumina
TotalPrep RNA amplification kit (Ambion, Inc., Austin,
TX, USA) was used to obtain biotin-labeled cRNA from
500 ng total RNA. As a control probe, normal human lung
poly(A) RNA (BD Biosciences Clontech) was amplified
under the same conditions. cRNA was synthesized
overnight (18 h), labeled, and hybridized to the chip at
58 °C overnight. Hybridized arrays were labeled with
streptavidin-Cy3 (PA43001; Amersham, Buckinghamshire,
UK) and scanned with an Illumina BeadArray reader
(Illumina Inc.). Scanned images were imported into Bead-
Studio v3 software (Illumina Inc.) for extraction, quality
adjustment, and quantile normalization. Satisfactory qual-
ity was observed for all arrays and samples.
Functional and canonical pathway analyses
The microarray gene expression data was analyzed
using Ingenuity Pathway Analysis (IPA; Ingenuity Sys-
tems, Redwood City, CA, USA) to determine whether
genes associated with particular diseases, biological
functions, or canonical signaling pathways were prefer-
entially up- or downregulated in IIP patients relative to
control subjects. Diseases and biological functions for
which differential gene expression was observed were
grouped into three categories: (1) diseases and disor-
ders; (2) molecular and cellular functions; and (3)
physiological system development and function.
Clustering analysis of microarray data
To assess the difference and similarity in the gene ex-
pression profile between IPF and NSIP, a hierarchical
clustering method was applied to genes and IIP sub-
types. To obtain reproducible clusters for classifying the
12 IIP patients, 159 genes were selected for which valid
data was obtained in 80% of the experiments, and whose
expression ratios varied by standard deviations of >3.0.
Gene Cluster 3.0 and Java TreeView software developed
by Eisen et al. were used to analyze the data [23, 24]. Be-
fore applying the clustering algorithm, the fluorescence
ratio for each spot was log-transformed and the data for
each sample was median-centered to remove experimen-
tal biases.
Immunohistochemical staining and morphometric
analysis
To evaluate the protein expression of two upregulated
genes, desmoglein 3 (DSG3) and Krebs von den lungen-
6 (KL-6)/Mucin 1 (MUC1), clinical tissue sections from
5 IPF patients, 5 NSIP patients, and 5 control lungs were
stained using ENVISION+ Kit/horseradish peroxidase
(HRP) (Dako Japan, Tokyo, Japan), as previously de-
scribed [25]. For antigen retrieval, slides were immersed
in Target Retrieval Solution, Citrate pH 6 (Dako Japan)
and boiled at 108 °C for 15 min in an autoclave. After
blocking endogenous peroxidase activity with 0.03% H2O2
for 30 min, sections were incubated with mouse anti-
human DSG3 (Clone #216519; R&D Systems, Minneap-
olis, MN, USA) and KL-6 antibodies, which were purified
as previously described [26]. The slides were then treated
with HRP-labeled anti-mouse IgG secondary antibody
followed by the addition of a chromogenic substrate. Sec-
tions were counterstained with hematoxylin. Image-Pro
Plus 6.3 (Media Cybernetics. Inc. Rockville, MD, USA)
was used for morphometric analysis to quantify the posi-
tively stained areas in the lung tissue, as previously de-
scribed [27].
Statistical analyses
Data were analyzed with SPSS for Windows, version 18.0
(SPSS Inc. Chicago, IL, USA) and are presented as
mean ± SEM. Data for individual variables from the vari-
ous groups were analyzed by the Kruskal-Wallis test
followed by multiple comparisons using rank sums [28].
Mean differences were considered statistically significant
at P < 0.05.
Results
Identification of genes up−/downregulated in IIP
Clinical characteristics of the 12 patients with chronic
fibrosing IIP (IPF, n = 7; NSIP, n = 5) analyzed by micro-
array were shown in Table 1. In total, 98 genes were upreg-
ulated while 1193 were downregulated in the lung tissue of
IIP patients compared to control subjects, based on expres-
sion ratios that were >20.0 or <0.05 respectively, in at least
75% (i.e., 9 out of 12) of informative cases. The top 50
genes upregulated in IIP are listed in Table 2. Some of the
upregulated genes, namely DSG3, protocadherin gamma-
A9 (PCDHGA9) and discoidin domain-containing receptor
1 (DDR1) are implicated in cell-cell interaction and/or ad-
hesion; some, namely collagen type VII, alpha 1 (COL7A1),
contactin-associated protein-like 3B (CNTNAP3B) and
MUC1 are encoding the extracellular matrix molecule or
the molecules involved in cell-matrix interactions; and the
others, namely CDC25C and growth factor independent
protein 1B (GFI1B) are known to affect cell prolifera-
tion by affecting the progression of cell cycle or regulat-
ing transcription. Of these, DDR1 and KL-6/MUC1
have been previously reported as biomarkers for ILD
[29, 30]. On the other hand, the top 50 genes downreg-
ulated in IIP are listed in Table 3. Some of these,
namely Defensin alpha 1 (DEFA1), DEFA3 and Mucin 7
(MUC7) are known to play important roles in anti-
microbial defense system in upper respiratory tract.
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Additionally, we also found that interleukin 10 (IL-10),
which is known to be one of the inhibitor of Th1 cells
was significantly downregulated.
Functional and canonical pathway analyses
As shown in Table 4, IPA software revealed that the most
highly-altered entry in IIP patients relative to control sub-
jects for (1) diseases and disorders; (2) molecular and cel-
lular functions; and (3) physiological system development
and function was cancer, cellular movement, and cardio-
vascular system respectively. The top five canonical signal-
ing pathways associated with the genes were antigen
presentation pathway, cytotoxic T lymphocyte-mediated
apoptosis of target cells, dendritic cell maturation, mo-
lecular mechanisms of cancer, and crosstalk between den-
dritic cells and natural killer cells. Thus, a number of
genes and pathways related to cancer, cell death and sur-
vival, and cellular growth and proliferation were differen-
tially expressed in IIP patients.
Clustering analysis of IPF and NSIP
An unsupervised two-dimensional hierarchical clustering
algorithm was used to analyze similarities among sam-
ples and genes by using data obtained from expression
profiles of 12 patients with IIP (Fig. 1). After filtering
using the criteria described in materials and methods,
159 genes remained. As shown in the dendrogram, three
major groups—IPF1–4, IPF5–7 and NSIP1, and NSIP2–
5—were distinguishable based on expression data, sug-
gesting that the transcriptional profiles of IPF and NSIP
were similar (Fig. 1).
Table 2 Top 50 genes upregulated in idiopathic interstitial
pneumonia (IIP) patients
Gene
symbol
Gene name Fold change
Fibrotic IIP/
control
DSG3 Desmoglein 3 321.2
KLRD1 Killer cell lectin-like receptor subfamily D,
member 1
252.8
OTUB1 OTU domain, ubiquitin aldehyde binding 1 246.7
ZFP92 ZFP92 zinc finger protein 222.9
NLGN4Y Neuroligin 4, Y-linked 217.2
GLB1L3 Galactosidase, beta 1-like 3 214.8
CDC25C Cell division cycle 25C 211.4
CNTNAP3B Contactin-associated protein-like 3B 186.3
SRGAP2 SLIT-ROBO Rho GTPase-activating protein 2 174.5
NEK3 NIMA-related kinase 3 167.0
SYT8 Synaptotagmin VIII 156.9
TLR10 Toll-like receptor 10 145.6
DST Dystonin 140.3
COL7A1 Collagen type VII, alpha 1 139.4
UTY Ubiquitously transcribed tetratricopeptide
repeat-containing, Y-linked
127.8
CYorf15A Chromosome Y open reading frame 15A 121.8
PCDHGA9 Protocadherin gamma subfamily A, 9 120.9
OXTR Oxytocin receptor 111.8
AIM2 Absent in melanoma 2 107.5
TMSB4Y Thymosin beta 4, Y-linked 106.4
YBEY ybeY metallopeptidase 104.4
UBE2D2 Ubiquitin-conjugating enzyme E2D 2 102.7
DDR1 Discoidin domain receptor tyrosine kinase 1 99.2
ZFY Zinc finger protein, Y-linked 98.0
SLC17A9 Solute carrier family 17, member 9 98.0
EIF1AY Eukaryotic translation initiation factor 1A, Y-
linked
96.8
ANO9 Anoctamin 9 91.6
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3,
Y-linked
88.7
HBS1L HBS1-like (S. cerevisiae) 88.6
MSL3 Male-specific lethal 3 homolog
(D. melanogaster)
85.2
MUC1 Mucin 1, cell surface-associated 83.3
PLCH2 Phospholipase C, eta 2 82.5
LPGAT1 Lysophosphatidylglycerol acyltransferase 1 81.8
DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 80.4
SDK2 sidekick cell adhesion molecule 2 79.2
C1QTNF1 C1q and tumor necrosis factor related
protein 1
78.8
ZRANB2 zinc finger, RAN-binding domain
containing 2
78.6
Table 2 Top 50 genes upregulated in idiopathic interstitial
pneumonia (IIP) patients (Continued)
ZNF300 zinc finger protein 300 76.9
DMBT1 deleted in malignant brain tumors 1 76.7
GFI1B growth factor independent 1B
transcription repressor
75.1
SLFN13 schlafen family member 13 72.1
CDK5RAP3 CDK5 regulatory subunit associated
protein 3
70.8
SLCO3A1 solute carrier organic anion transporter
family, member 3A1
70.5
SNRNP70 small nuclear ribonucleoprotein 70
kDa (U1)
66.2
IL18BP interleukin 18 binding protein 64.7
PCNXL2 pecanex-like 2 (Drosophila) 64.6
ZSCAN29 zinc finger and SCAN domain
containing 29
63.7
ESR2 estrogen receptor 2 (ER beta) 62.5
FBXO41 F-box protein 41 61.7
MRPL20 mitochondrial ribosomal protein L20 61.3
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Validation of gene array data with immunohistochemistry
To validate the gene expression data at protein level, we
selected two of the upregulated genes, DSG3 and KL-6/
MUC1, for immunohistochemical analysis. DSG3 showed
the highest upregulation in gene expression analysis, indi-
cating its potential as a novel biomarker for IIPs. KL-6/
MUC1 is well studied and is a clinically approved bio-
marker for IIPs [26, 30–33]. Clinical characteristics of the
10 patients with IIPs included in the immunohistochemi-
cal analysis were similar to those of the patients included
in the microarray analysis (Table 1). As shown in Fig. 2a,
DSG3 was mainly detected in the bronchiolar/alveolar
epithelium and to a lesser extent in the fibrotic intersti-
tium in IIP patients. The percentage of DSG3-positive
areas in both IPF and NSIP lungs were significantly
higher than those in control lungs (Fig. 2c). In agree-
ment with earlier studies [26, 30, 33], KL-6/MUC1 was
expressed by type II pneumocytes in all the lung speci-
mens (Fig. 2b). Furthermore, continuous KL-6/MUC1
staining was observed on the cell surface of regenerat-
ing type II pneumocytes in IIP patients, in contrast with
normal lung tissue in which a discontinuous pattern
was observed (Fig. 2b). The percentage of KL-6/MUC1-
positive areas in both IPF and NSIP lung were signifi-
cantly higher than that in control lungs (Fig. 2d).
Discussion
A genome-wide gene expression analysis revealed that
several genes were up- or downregulated in the lung tissue
of Japanese IIP patients compared to control subjects.
Among them, DSG3 showed the highest upregulation in
IIP lung as compared to control lung, and was considered
to be a potential novel biomarker for IIPs. Subsequently,
the function and pathway analysis demonstrated that
genes and pathways related to cancer, cell death and
survival, and cellular growth and proliferation were
Table 3 Top 50 known genes downregulated in IIP patients
Gene
symbol
Gene name Fold change
Fibrotic IIP/
control
PRB2 Proline rich protein BstNI subfamily 2 8.35E-04
DEFA3 Defensin alpha 3 9.05E-04
DEFA1 Defensin alpha 1 1.09E-03
PRB1 Proline rich protein BstNI subfamily 1 1.21E-03
HLA-DRB5 Major histocompatibility complex,
class II, DR beta 5
1.38E-03
CYP1A2 Cytochrome P450 family 1 subfamily A
member 2
1.59E-03
VNN2 Vanin 2 1.73E-03
MUC7 Mucin 7 1.82E-03
PRB3 Proline rich protein BstNI subfamily 3 1.85E-03
FPR2 Formyl peptide receptor 2 1.88E-03
WDR47 WD repeat domain 47 1.90E-03
HLA-C Major histocompatibility complex, class I, C 1.91E-03
HIST1H2BD Histone cluster 1 H2B family member d 1.94E-03
CCRL1 Chemokine (C-C motif) receptor-like 1 2.00E-03
UMOD Uromodulin 2.09E-03
HIST1H1E Histone cluster 1 H1 family member e 2.11E-03
HIST1H2AE Histone cluster 1 H2A family member e 2.19E-03
FCAR Fc fragment of IgA receptor 2.24E-03
SLCO1A2 Solute carrier organic anion transporter
family member 1A2
2.26E-03
RNASE3 Ribonuclease A family member 3 2.27E-03
WWP2 WW domain containing E3 ubiquitin
protein ligase 2
2.33E-03
BPIFB2 BPI fold containing family B member 2 2.34E-03
LPO Lactoperoxidase 2.40E-03
ITLN1 Intelectin 1 2.42E-03
NAIP NLR family apoptosis inhibitory protein 2.42E-03
CCDC85A Coiled-coil domain containing 85A 2.46E-03
MAP4 Microtubule associated protein 4 2.50E-03
PRH2 Proline rich protein HaeIII subfamily 2 2.54E-03
IL10 Interleukin 10 2.59E-03
CELA2A Chymotrypsin like elastase family
member 2A
2.63E-03
RGPD1 RANBP2-like and GRIP domain containing 1 2.64E-03
LAT2 Linker for activation of T-cells family
member 2
2.66E-03
LRCH1 Leucine rich repeats and calponin
homology
domain containing 1
2.67E-03
HFE Hemochromatosis 2.79E-03
GPM6A Glycoprotein M6A 2.81E-03
APOL1 Apolipoprotein L1 2.84E-03
FCGR3B Fc fragment of IgG receptor IIIb 2.89E-03
S100A12 S100 calcium binding protein A12 2.92E-03
Table 3 Top 50 known genes downregulated in IIP patients
(Continued)
CCK Cholecystokinin 2.93E-03
FCRL6 Fc receptor like 6 2.94E-03
OPRPN Opiorphin prepropeptide 2.96E-03
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 2.98E-03
C8orf37 chromosome 8 open reading frame 37 3.02E-03
TCN1 Transcobalamin 1 3.06E-03
HIST1H4I Histone cluster 1 H4 family member i 3.11E-03
SLC22A12 Solute carrier family 22 member 12 3.14E-03
RGPD5 RANBP2-like and GRIP domain containing 5 3.26E-03
PRTG Protogenin 3.32E-03
C8B Complement C8 beta chain 3.38E-03
CLEC4M C-type lectin domain family 4 member M 3.46E-03
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differentially expressed in Japanese IIP patients. These re-
sults suggest the possibility that several molecules in-
volved in cancer cell growth can be novel biomarkers that
can potentially be used for diagnosis or serve as thera-
peutic targets for IIPs.
In total, 98 genes were upregulated in the lung tissue
of Japanese IIP patients compared to control subjects.
Among the upregulated genes, DSG3 showed the highest
upregulation indicating its potential as a novel bio-
marker for IIPs. DSG3, a member of desmoglein family,
is a calcium-binding transmembrane glycoprotein com-
ponent of desmosomes in epithelial cells [34]. Under
normal conditions, DSG3 is expressed in oral mucosa
and esophagus, but not in lungs [34]. Therefore, DSG3
expression in IIP lung may be due to the differences in
cell adhesion properties between normal pneumocytes
and regenerative pneumocytes in IIP lung. Our study
shows for the first time that DSG3 expression is sig-
nificantly different between IPF or NSIP lungs and the
control lungs, suggesting a novel biomarker for the diag-
nosis of IIP. Actually, it has been reported that DSG3
can be the useful biomarker for squamous cell lung can-
cer [35]. As IIP and squamous cell lung cancer often
occur simultaneously, both of these diseases may share
the similar pathogenesis especially in the way cell adhe-
sion properties are altered. In addition, some other mole-
cules, which are known to be involved in cell-cell
interaction and/or adhesion, were also shown to be upregu-
lated. For example, KL-6/MUC1, which has been approved
by Japan’s Health Insurance Program as a diagnostic
marker for ILDs since 1999 and is currently in wide clinical
use in Japan was upregulated in IIP lungs. Given that the
key pathologic features of IIPs are considered to be epithe-
lial cell damage and abnormal regeneration [36], we believe
that our results from gene expression analysis are quite rea-
sonable since these cell adhesion molecules are abundantly
expressed in IIP tissues.
Other upregulated genes included transmembrane/
secretory proteins such as DDR1, killer cell lectin-like re-
ceptor subfamily D member 1 (KLRD1) and toll-like recep-
tor 10 (TLR10). These may also act as useful biomarkers
since their cell surface localization makes them easily ac-
cessible to diagnostic methods and therapeutics. The bio-
logical and clinicopathologic significance of these candidate
genes awaits validation through analysis of protein expres-
sion profiles in lung tissue obtained from IIP patients, as
Table 4 Top 5 functional and canonical pathways from the Ingenuity Pathway Analysis
Functional analysis/name P value Number of molecules
Diseases and disorders
Cancer 2.47E − 09–4.63E − 03 770
Renal and urological disease 3.66E − 08–3.83E − 03 99
Inflammatory response 6.96E − 08–4.28E − 03 263
Immunological disease 3.91E − 07–3.15E − 03 219
Hematological disease 4.54E − 07–4.41E − 03 141
Molecular and cellular functions
Cellular movement 5.28E − 11–4.43E − 03 295
Cell death and survival 2.11E − 07–4.72E − 03 437
Cell morphology 8.16E − 07–4.94E − 03 105
Cellular growth and proliferation 1.51E − 06–4.17E − 03 423
Cellular development 2.62E − 06–4.92E − 03 372
Physiological system development and function
Cardiovascular system development and function 1.54E − 08–4.83E − 03 208
Organismal development 3.30E − 08–4.83E − 03 260
Hematological system development and function 6.96E − 08–4.92E − 03 258
Immune cell trafficking 6.96E − 08–4.43E − 03 268
Embryonic development 8.16E − 07–3.34E − 03 147
Canonical pathway analysis/name P value Ratio
Antigen presentation pathway 1.89E − 05 12/42 (0.286)
Cytotoxic T lymphocyte-mediated apoptosis of target cells 1.35E − 04 12/88 (0.136)
Dendritic cell maturation 1.48E − 04 28/211 (0.133)
Molecular mechanisms of cancer 2.27E − 04 47/387 (0.121)
Crosstalk between dendritic cells and natural killer cells 2.7E − 04 18/106 (0.170)
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well as functional assays such as gene knockdown. Their
potential as diagnostic markers in serum can be evaluated
by enzyme-linked immunosorbent assay [37], but a pos-
sible caveat is that gene expression in lung tissue and
serum levels of the gene product are not always correlated.
More recently, a mass spectrometry-based technique,
multiple reaction monitoring, has proven to be a useful
method for detecting proteins without specific antibodies
[38, 39]. Thus, a high-throughput serum proteome ana-
lysis using this system combined with microarray gene ex-
pression profiling would be ideal for selecting candidate
serum biomarkers.
We also demonstrated that lot of genes are downregu-
lated in the lung tissue of Japanese IIP patients (Table 3).
Among them, DEFA 1 and 3 are strongly downregulated;
these genes are known to belong to human neutrophil
peptides (HNPs) and the serum levels of HNPs have
been reported to be elevated in patients with interstitial
pneumonia associated with systemic sclerosis [40] and
also in those with acute exacerbation of IIPs [41]. Our
results would support the hypothesis that HNPs play im-
portant roles in the pathogenesis of IIPs. In addition, we
also found that IL-10, which has been known as an in-
hibitor of cytokine production by Th1 cells is downregu-
lated. As Th1 cytokine has been demonstrated to play
important role in the progression of lung fibrosis [42],
we can speculate that the downregulation of IL-10 ac-
companied with increased production of Th1 cytokine
may strongly promote the fibrotic change in the lung.
Interestingly, IPA analysis in our study revealed that IIP
had a profile that was more similar to cancer than to in-
flammatory responses and immunological diseases. These
findings were in marked contrast to those in patients with
chronic hypersensitivity pneumonitis (CHP); several
Fig. 1 The dendrogram (top) shows similarities between samples, with shorter branches indicating a higher degree of similarity. The heat map
(bottom) shows the expression level of 159 genes in each case. Red: upregulated genes; green: downregulated genes. In the right panel, the
names of 159 genes are listed
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pathways related to inflammatory responses and immuno-
logical diseases were differentially expressed in patients
with CHP [43]. The canonical pathway analysis implicated
dendritic cell maturation and molecular mechanisms of
cancer pathways in IIP; indeed, the dendritic cell matur-
ation signaling pathway is targeted by several molecular tar-
geted agents mainly for chronic myelogenous leukemia
such as nilotinib and dasatinib which inhibit Bcr-Abl tyro-
sine kinase activity [44, 45]. We speculate that these mo-
lecular targeted agents which interferes the dendritic cell
maturation signaling pathway may also be beneficial for
IIPs. Further study is required to determine whether these
agents can, in fact, limit the progression of pulmonary
fibrosis.
The differentially expressed genes and pathways in the
patients with IIPs identified in the present study showed
substantial overlap with those reported in the previous
studies [17–19]. Selman M. et al. and Yang IV. et al. re-
ported that genes encoding extracellular matrix mole-
cules, cell surface molecules and cell adhesion molecules
were highly expressed in IPF [17, 19]. In our study,
COL7A1, which is involved in the extracellular matrix,
MUC1, KLRD1 and TLR10, which are the cell surface
molecules, and PCDHGA9 and DSG3, which are in-
volved in cell-cell adhesion are upregulated in the pa-
tients with IIPs as compared to control. In addition, our
results that functional pathways related to cellular
growth and development are differentially expressed in
the patients with IIPs as compared to control are similar
to the results reported by Selman et al. [17]. Based on
these results, we can speculate that the genes and path-
ways differentially expressed in the patients with IIPs are
not much different between Japanese and Caucasians.
The transcriptional profiles of IPF and NSIP were
similar and only minor differences in gene expression
were identified, consistent with the results of several
previous investigations [18, 19]. It is still possible that
differences exist and may have been detected if multiple
samples from different lobes of the lung had been separ-
ately analyzed, since lung disease by nature has a patchy
distribution and also because IPF and NSIP may coexist
in the same lung [46, 47]. Moreover, fibrotic NSIP in
some patients has a presentation similar to IPF. The
classification of IPF and fibrotic NSIP as separate dis-
eases has recently been challenged, and it has been sug-
gested that they share a common clinical phenotype and
pathogenesis [48]. Importantly, patients with NSIP
included in the present study were mostly consisted of
fibrotic NSIP. The results presented here lend support
to the reclassification of these IIP subtypes as a single
clinical entity.
Although this study showed promising results, it has
some limitations. First, control RNA for microarray ana-
lysis was derived from Caucasian subjects, because control
RNA derived from Japanese subjects was not commer-
cially available. Considering the ethnic differences in the
relationship between genetic variants and the presence of
IIP [49, 50], we cannot apply the results from the present
study to Japanese patients with IIP without validation
study. Second, the number of the subjects included in the
a b
c d
Fig. 2 The expression of (a) DSG3 and (b) KL-6/MUC1 are strong in the lung affected by IPF or NSIP as compared to the controls. Morphometric
analysis for (c) DSG3 and (d) KL-6/MUC1 confirmed that the rate of positively stained area is significantly high in the lung affected by IPF or NSIP
as compared to the controls. *P < 0.05; **P < 0.01; ***P < 0.001
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immunohistochemical analysis is relatively small. We need
further prospective studies with larger sample size in order
to confirm the utility of DSG3 as the biomarker for IIPs.
Conclusions
To summarize, the genome-wide gene expression analysis
of Japanese IIP patients revealed a set of upregulated
genes including DSG3, a promising novel biomarker for
IIPs. The differentially expressed genes between IIP pa-
tients and controls are implicated in cancer, cell death and
survival, and cellular growth and proliferation. This data-
set provides a resource for future studies investigating the
molecular mechanisms underlying the development and
progression of pulmonary fibrosis as well as a collection of
molecules that can be targeted by novel therapeutics.
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